Gapping down
In reaction to disappointing earnings/guidance:
- ORCL -3.3%, GAN -3.1%
Other news:
- CEMI -60.6% (disclosed that the FDA was revoking the Emergency Use Authorization granted in April 2020 with respect to DPP COVID-19 System)
- AVEO -12.6% (prices offering of 8,500,000 shares of its common stock at $5.25 per share)
- IFRX -8.2% (announces interim results from the first 30 patients treated in the adaptive randomized Phase II/III trial in patients with severe COVID-19 pneumonia)
- NCLH -7.7% (extends suspension of certain voyages through Sep 30)
- DKNG -5.1% (files for 14 mln share offering plus 19 mln share offering by selling shareholders)
- PRVB -4.8% (commences public offering of 5.5 mln shares)
- FCEL -4.6% (entered into $75 mln open market sale agreement with Jefferies pursuant to shelf registration statement)
- RCL -4% (down in sympathy with NCLH)
- BKI -3.9% (prices offering is for 6,200,000 shares of its common stock for gross proceeds of $435.55 mln)
- CCL -3.1% (down in sympathy with NCLH)
- IR -2.8% (offering of 12.1 mln shares by selling stockholder)
- CUK -2.4% (down in sympathy with NCLH)
- NSTG -1.2% (announces new products to be used for COVID-19 research)
- CNST -1.1% (prices offering of 5,500,000 shares of its common stock at $35.00 per share)
Analyst comments:
- NDSN -1.3% (downgraded to Sector Weight from Overweight at KeyBanc Capital Markets)